Research Papers:

Systematic evaluation of cancer risk associated with rs2292832 in miR‑149 and rs895819 in miR‑27a: a comprehensive and updated meta‑analysis

Yajing Feng _, Fujiao Duan, Chunhua Song, Xia Zhao, Liping Dai and Shuli Cui

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:22368-22384. https://doi.org/10.18632/oncotarget.8082

Metrics: PDF 2149 views  |   HTML 2013 views  |   ?  


Yajing Feng1, Fujiao Duan2, Chunhua Song3, Xia Zhao2, Liping Dai3, Shuli Cui4

1Department of Infection Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, P.R.China

2Department of Hospital Infection Management, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan, P.R.China

3Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan, P.R.China

4College of Professional Study, Northeastern University, Boston, 02215 Massachusetts, USA

Correspondence to:

Yajing Feng, e-mail: [email protected]

Fujiao Duan, e-mail: [email protected]

Keywords: miR-149, miR-27a, cancer, susceptibility, systematic evaluation

Received: November 05, 2015     Accepted: February 24, 2016     Published: March 14, 2016


The aim of this study is to provide a precise quantification for the association between miR-149 T > C (rs2292832) and miR-27a A > G (rs895819) and the risk of cancer. We conducted a systematic literature review and evaluated the quality of included studies based on Newcastle-Ottawa Scale (NOS). Pooled odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were calculated to assess the strengths of the associations. We identified 40 studies for pooled analyses. Overall, the results demonstrated that the rs2292832 polymorphism was subtly decrease the risk of breast cancer (CT + CC vs TT: OR = 0.83, 95% CI: 0.70–0.98, P = 0.03; CC vs CT + TT: OR = 0.80, 95% CI: 0.68–0.93, P = 0.00), and the rs895819 polymorphism wasassociated with significantly increased cancer risk in the Asian population (AG + GG vs AA: OR = 1.24, 95% CI: 1.03–1.50, P = 0.02) and in colorectal cancer subgroup (GG vs AA: OR = 1.45, 95% CI: 1.10–1.92, P = 0.00; AG + GG vs AA: OR = 1.35, 95% CI: 1.15–1.58, P = 0.00; GG vs AG + AA: OR = 1.36, 95% CI: 1.04–1.77, P = 0.02). In addition, a subtly decreased risk was observed in the Caucasian population and in breast cancer subgroup. In conclusion, the rs2292832 polymorphism was significantly associated with increased breast cancer risk, and the rs895819 polymorphism contributes to the susceptibility of colorectal and breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8082